Previously, a single-arm, non-randomized feasibility study in HER2+ metastatic breast cancer patients (n = 20) was done using a HER2+ whole-cell breast cancer vaccine and weekly trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.